Navigation Links
Dendreon Corporation CEO Mitchell H. Gold, M.D. Named Ernst & Young Entrepreneur of the Year(R) 2009 Award Finalist in the Pacific Northwest
Date:5/14/2009

eur Of The Year awards are pleased to have the Ewing Marion Kauffman Foundation and SAP America as national sponsors.

In the Pacific Northwest, sponsors include The Big Picture Film and Video Arts, Scherzer International, Seattle Business and The Summit Group.

About Dendreon

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response. Dendreon is also developing an orally-available small molecule that targets TRPM8 that could be applicable to multiple types of cancer as well as benign prostatic hyperplasia. The Company has its headquarters in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN. For more information about the Company and its programs, visit www.dendreon.com.

About Ernst & Young's Entrepreneur Of The Year(R) Awards Program

Ernst & Young's Entrepreneur Of The Year(R) Award is the world's most prestigious business award for entrepreneurs. The award makes a difference through the way it encourages entrepreneurial activity among those with potential and recognizes the contribution of people who inspire others with their vision, leadership and achievement. As the first and only truly global award of its kind, the Ernst & Young Entrepreneur Of The Year(R) award celebrates those who are building and leading successful, growing and dynamic businesses, recognizing them through regional, national and global awards programs in more than 135 cities in 50 countries.


'/>"/>
SOURCE Dendreon Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Dendreon Announces Webcast Presentation at UBS Life Sciences Conference
3. Dendreon Secures $130 Million Committed Equity Financing Facility
4. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
5. Dendreon Reports Third Quarter 2007 Financial Results
6. Dendreon Promotes Dr. Mark Frohlich to Senior Vice President of Clinical Affairs and Chief Medical Officer
7. Dendreon Announces Webcast Presentation at BIO CEO & Investor Conference
8. Dendreon Publishes Manuscript on CD54 as a Surrogate Marker of Antigen Presenting Cell Activation
9. -Dendreon to Hold Conference Call on Thursday, March 13, 2008 at 11:00 AM ET-
10. FDA Agrees to Amend Dendreons Special Protocol Assessment for Phase 3 IMPACT Study of PROVENGE
11. Dendreon Reports Fourth Quarter and 2007 Year End Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... April 27, 2015 Dr. Robert Hanzlik, ... chemical toxicity carries implications for advancing the creation of ... at National University , the second-largest private, nonprofit ... Dr. Hanzlik, a professor at the University of Kansas ... drug design, starts at 5 p.m. and takes place ...
(Date:4/27/2015)... 27, 2015 Deadly viruses such as ... resident of the University City Science Center's ... , With a $4.5 million Phase 2 SBIR ... Phelix Therapeutics is focused on therapies for ... The company is developing first-in-class protease inhibitors based on ...
(Date:4/27/2015)... -- Editor Note: For more ... . Investor-Edge has initiated coverage on ... LXRX ), Idera Pharmaceuticals Inc. (NASDAQ: IDRA ... Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI ), and ... report on Lexicon Pharma can be accessed at ...
(Date:4/27/2015)... 2015 SynGen Inc., a company that focuses ... harvest stem and progenitor cells from umbilical cord blood, ... that it has added three new members to its ... Business Units focus on product commercialization. ... Vice President and Chief Financial Officer.  Chuck was most ...
Breaking Biology Technology:Dr. Robert Hanzlik Discusses Pharmaceutical Testing Models at Event Hosted by National University 2Dr. Robert Hanzlik Discusses Pharmaceutical Testing Models at Event Hosted by National University 3New Resident of Science Center’s Port Business Incubator Targets SARS and Ebola 2Market Updates on Biotech Stocks -- Lexicon Pharma, Idera Pharma, Synta Pharma, Spectrum Pharma, and Medivation 2Market Updates on Biotech Stocks -- Lexicon Pharma, Idera Pharma, Synta Pharma, Spectrum Pharma, and Medivation 3Market Updates on Biotech Stocks -- Lexicon Pharma, Idera Pharma, Synta Pharma, Spectrum Pharma, and Medivation 4Market Updates on Biotech Stocks -- Lexicon Pharma, Idera Pharma, Synta Pharma, Spectrum Pharma, and Medivation 5SynGen Inc. Expands Its Management Team 2
... BioLife Solutions, Inc. (OTCBB: BLFS), a leading developer ... for cells and tissues, today announced that it ... cryopreservation media for umbilical cord blood stem cells, ... market. BioLife Solutions, which will be exhibiting at ...
... University say they have discovered a simple method for ... nanostructure that some believe could replace silicon as the ... intense scientific research in recent years, graphene is a ... atoms arranged in a hexagonal lattice. It is the ...
... Drs. Samuel and Elenore Bogoch of BioRadar UK Ltd. announced ... of the EHEC lethal strains of E. Coli preceded the ... have been studied in laboratories in Germany and elsewhere since ... databases. Replikins are subsequences of the genome of an infectious ...
Cached Biology Technology:BioLife Solutions Now The Leading Supplier of Pre-Formulated GMP Cryopreservation Media for Umbilical Cord Blood Stem Cells 2BioLife Solutions Now The Leading Supplier of Pre-Formulated GMP Cryopreservation Media for Umbilical Cord Blood Stem Cells 3Northern Illinois University scientists find simple way to produce graphene 2Rising Replikin Counts in E. Coli in Germany Since 2005 Preceded Current E. Coli Outbreak 2Rising Replikin Counts in E. Coli in Germany Since 2005 Preceded Current E. Coli Outbreak 3
(Date:4/14/2015)... 14, 2015  HYPR Corp. today announced it ... ) Alliance tm , an industry consortium transforming ... to share technology and collaborate to deliver open ... more secure and private, and easier to use. ... that protects sensitive user information and eliminates the ...
(Date:4/13/2015)... , April 13, 2015 ... TechSci Research, "Global Biometrics Market Forecast & Opportunities, 2020", ... a CAGR of around 14% till 2020. The ... for large scale implementation and review of biometric ... launch of new products with greater efficiency, are ...
(Date:4/10/2015)... , April 10, 2015 Research ... of the "Security Competitive Profiles - NEC" ... , NEC will continue to supply a ... the market, with a company focus on the development ... Winning opportunities in the Asia-Pacific ...
Breaking Biology News(10 mins):HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2NEC Security Competitive Profile 2015 2
... learning more about how protein gets in the urine when ... blocks it. "We have known for a long time ... in diabetes," said Dr. David Pollock, renal physiologist at the ... that a new class of drugs called endothelin A receptor ...
... days of critical international discussion and debate, led by ... Clinical Densitometry (ISCD) and the International Osteoporosis Foundation (IOF), ... pertaining to the interpretation and use of FRAX in ... Tool (FRAX), with models for some 26 countries, is ...
... that applying a stem cell-infused patch together with overexpression ... to damaged cardiac tissue following heart attack and resulted ... also found that function improved more so than when ... that is being studied elsewhere. These findings are ...
Cached Biology News:Scientists learn more about how kidneys fail and how new drugs may intervene 2International discussions on FRAX smooth the way for implementation in clinical practice 2Stem cell patch may result in improved function following heart attack 2Stem cell patch may result in improved function following heart attack 3
... depletion cocktail is tailored to ... from suspensions of rat spleen ... the StemSep (or compatible 0.5 ... system. The CD4+ T cell ...
Preparation TW--Compatibility: Push-on end cap seals suitable up to 70 C only -Hybridization Tube for Model HB-1D -Comp Dim: 200 80 mm -Material: borosilicate glass -Mfr Desig: Techne FHB-12...
Preparation TW--Compatibility: no end cap seals -Hybridization Tube for Hybrigene -Comp Dim: 240 80 mm -Material: borosilicate glass -Mfr Desig: Techne FHB-15...
...
Biology Products: